<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Alumis Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/alumis-inc-common-stock</link>
<description>Latest news and press releases for Alumis Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Sat, 28 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/alumis-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835455378dffbe2df0e2820.webp</url>
<title>Alumis Inc. Common Stock</title>
<link>https://6ix.com/company/alumis-inc-common-stock</link>
</image>
<item>
<title>Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis</title>
<link>https://6ix.com/company/alumis-inc-common-stock/news/alumis-envudeucitinib-delivers-early-and-robust-improvements-in-skin-clearance-quality-of-life-and-psoriasis-symptoms-in-two-phase-3-trials-underscoring-its-potential-as-a-leading-oral-therapy-for-plaque-psoriasis</link>
<guid isPermaLink="true">https://6ix.com/company/alumis-inc-common-stock/news/alumis-envudeucitinib-delivers-early-and-robust-improvements-in-skin-clearance-quality-of-life-and-psoriasis-symptoms-in-two-phase-3-trials-underscoring-its-potential-as-a-leading-oral-therapy-for-plaque-psoriasis</guid>
<pubDate>Sat, 28 Mar 2026 04:00:00 GMT</pubDate>
<description>Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%,</description>
</item>
<item>
<title>Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements</title>
<link>https://6ix.com/company/alumis-inc-common-stock/news/alumis-reports-year-end-2025-financial-results-and-highlights-recent-achievements</link>
<guid isPermaLink="true">https://6ix.com/company/alumis-inc-common-stock/news/alumis-reports-year-end-2025-financial-results-and-highlights-recent-achievements</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>– Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety profile in</description>
</item>
<item>
<title>Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting</title>
<link>https://6ix.com/company/alumis-inc-common-stock/news/alumis-announces-late-breaker-oral-presentation-of-phase-3-data-for-envudeucitinib-in-moderate-to-severe-plaque-psoriasis-at-2026-american-academy-of-dermatology-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/alumis-inc-common-stock/news/alumis-announces-late-breaker-oral-presentation-of-phase-3-data-for-envudeucitinib-in-moderate-to-severe-plaque-psoriasis-at-2026-american-academy-of-dermatology-annual-meeting</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>– Phase 3 data presentation highlighting results from the ONWARD1 and ONWARD2 clinical trials of envudeucitinib – – Phase 2 STRIDE e-poster presentation to</description>
</item>
<item>
<title>Alumis to Present at the Leerink Partners Global Healthcare Conference</title>
<link>https://6ix.com/company/alumis-inc-common-stock/news/alumis-to-present-at-the-leerink-partners-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/alumis-inc-common-stock/news/alumis-to-present-at-the-leerink-partners-global-healthcare-conference</guid>
<pubDate>Mon, 02 Mar 2026 13:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026, at 10:40 a.m. ET. A live webcast will be available on the Alumis website in the “Invest</description>
</item>
<item>
<title>Alumis to Participate in Upcoming February Investor Conferences</title>
<link>https://6ix.com/company/alumis-inc-common-stock/news/alumis-participate-upcoming-february-investor-130500808</link>
<guid isPermaLink="true">https://6ix.com/company/alumis-inc-common-stock/news/alumis-participate-upcoming-february-investor-130500808</guid>
<pubDate>Thu, 05 Feb 2026 13:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences: Guggenheim Emerging Outlook: Biotech Summit 2026February 11-12, 2026, New York, NYFireside chat: Thursday, February 12, 2026 at 9:00 am ET Oppenheimer 36th Annual Healthcare Life Sciences ConferenceF</description>
</item>
<item>
<title>Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/alumis-inc-common-stock/news/alumis-announces-closing-upsized-public-210500721</link>
<guid isPermaLink="true">https://6ix.com/company/alumis-inc-common-stock/news/alumis-announces-closing-upsized-public-210500721</guid>
<pubDate>Fri, 09 Jan 2026 21:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the closing of its upsized underwritten public offering of 20,297,500 shares of its common stock, including the full exercise of the underwriters' option to purchase an additional 2,647,500 shares, at a price to the public of $17.00 per share. The gross procee</description>
</item>
<item>
<title>Alumis Announces Pricing of Upsized Public Offering of Common Stock</title>
<link>https://6ix.com/company/alumis-inc-common-stock/news/alumis-announces-pricing-upsized-public-035200667</link>
<guid isPermaLink="true">https://6ix.com/company/alumis-inc-common-stock/news/alumis-announces-pricing-upsized-public-035200667</guid>
<pubDate>Thu, 08 Jan 2026 03:52:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the pricing of an upsized underwritten public offering of 17,650,000 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds to Alumis from the offering, before deducting underwriting discounts and commissions and offering e</description>
</item>
<item>
<title>Alumis Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/alumis-inc-common-stock/news/alumis-announces-proposed-public-offering-211200462</link>
<guid isPermaLink="true">https://6ix.com/company/alumis-inc-common-stock/news/alumis-announces-proposed-public-offering-211200462</guid>
<pubDate>Tue, 06 Jan 2026 21:12:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced its plans to commence an underwritten public offering of $175.0 million of shares of its common stock. All of the shares are being offered by Alumis. In addition, Alumis expects to grant the underwriters a 30-day option to purchase up to an additional $26.25 m</description>
</item>
<item>
<title>Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program</title>
<link>https://6ix.com/company/alumis-inc-common-stock/news/alumis-envudeucitinib-delivers-leading-skin-120000931</link>
<guid isPermaLink="true">https://6ix.com/company/alumis-inc-common-stock/news/alumis-envudeucitinib-delivers-leading-skin-120000931</guid>
<pubDate>Tue, 06 Jan 2026 12:00:00 GMT</pubDate>
<description>– Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis...</description>
</item>
<item>
<title>Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis</title>
<link>https://6ix.com/company/alumis-inc-common-stock/news/alumis-host-conference-call-webcast-220000764</link>
<guid isPermaLink="true">https://6ix.com/company/alumis-inc-common-stock/news/alumis-host-conference-call-webcast-220000764</guid>
<pubDate>Mon, 05 Jan 2026 22:00:00 GMT</pubDate>
<description>– Conference Call and Webcast to be held Tuesday, January 6, 2026, at 8:00 a.m. ET – SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will report topline data from the Phase 3 ONWARD clinical program evaluating envudeucitinib in patients with moderate-to-severe plaque psoriasis on Tuesday, January 6, 20</description>
</item>
<item>
<title>Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress</title>
<link>https://6ix.com/company/alumis-inc-common-stock/news/alumis-reports-third-quarter-2025-211500022</link>
<guid isPermaLink="true">https://6ix.com/company/alumis-inc-common-stock/news/alumis-reports-third-quarter-2025-211500022</guid>
<pubDate>Thu, 13 Nov 2025 21:15:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for the quarter ended September 30, 2025, and highlighted recent achievements. “As we continue to advance our pipeline, we are entering an important period for Alumis. Our teams have been working diligently, and we are eagerly anticipating key</description>
</item>
<item>
<title>Alumis to Participate in Upcoming November Investor Conferences</title>
<link>https://6ix.com/company/alumis-inc-common-stock/news/alumis-participate-upcoming-november-investor-130000909</link>
<guid isPermaLink="true">https://6ix.com/company/alumis-inc-common-stock/news/alumis-participate-upcoming-november-investor-130000909</guid>
<pubDate>Tue, 04 Nov 2025 13:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences: Guggenheim’s 2nd Annual Healthcare Innovation ConferenceNovember 10-12, 2025, Boston, MAFireside chat: Tuesday, November 11, 2025 at 1:30 pm ET Stifel 2025 Healthcare ConferenceNovember 11-13, 2025,</description>
</item>
<item>
<title>Alumis to Participate in Upcoming September Investor Conferences</title>
<link>https://6ix.com/company/alumis-inc-common-stock/news/alumis-participate-upcoming-september-investor-110000850</link>
<guid isPermaLink="true">https://6ix.com/company/alumis-inc-common-stock/news/alumis-participate-upcoming-september-investor-110000850</guid>
<pubDate>Fri, 29 Aug 2025 11:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences: Cantor Global Healthcare Conference 2025 in New York, NY on September 3 at 9:45 am ET (fireside chat);Wells Fargo 2025 Healthcare Conference in Boston, MA on September 5 at 9:30 am ET (fireside chat)</description>
</item>
<item>
<title>Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/alumis-inc-common-stock/news/alumis-reports-second-quarter-2025-200500179</link>
<guid isPermaLink="true">https://6ix.com/company/alumis-inc-common-stock/news/alumis-reports-second-quarter-2025-200500179</guid>
<pubDate>Wed, 13 Aug 2025 20:05:00 GMT</pubDate>
<description>–Completed enrollment in Phase 3 ONWARD clinical trials for envudeucitinib in moderate-to-severe plaque psoriasis; topline readout expected in early Q1 2026– –Completed enrollment in Phase 2b LUMUS clinical trial for envudeucitinib in systemic lupus erythematosus (SLE); topline readout expected in Q3 2026– –Completed merger with ACELYRIN, Inc. to strengthen financial position and support advancement of late-stage immunology pipeline– –Cash, cash equivalents and marketable securities of $486.3 mi</description>
</item>
<item>
<title>Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus</title>
<link>https://6ix.com/company/alumis-inc-common-stock/news/alumis-completes-patient-enrollment-global-113000043</link>
<guid isPermaLink="true">https://6ix.com/company/alumis-inc-common-stock/news/alumis-completes-patient-enrollment-global-113000043</guid>
<pubDate>Thu, 24 Jul 2025 11:30:00 GMT</pubDate>
<description>-Topline Readout Expected in Q3 2026- SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the completion of patient enrollment in its global LUMUS Phase 2b trial of ESK-001, a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor, for the treatment of systemic lupus erythematosus (SLE), the most common</description>
</item>
<item>
<title>Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary</title>
<link>https://6ix.com/company/alumis-inc-common-stock/news/alumis-announces-promotion-sanam-pangali-200500440</link>
<guid isPermaLink="true">https://6ix.com/company/alumis-inc-common-stock/news/alumis-announces-promotion-sanam-pangali-200500440</guid>
<pubDate>Mon, 14 Jul 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary. Sanam most recently served as Senior Vice President, Legal of Alumis. In her new role, she will lead all legal and compliance functions, including corporate governance, intellectual property, a</description>
</item>
<item>
<title>Alumis to Present at the Jefferies Global Healthcare Investor Conference</title>
<link>https://6ix.com/company/alumis-inc-common-stock/news/alumis-present-jefferies-global-healthcare-201500957</link>
<guid isPermaLink="true">https://6ix.com/company/alumis-inc-common-stock/news/alumis-present-jefferies-global-healthcare-201500957</guid>
<pubDate>Thu, 29 May 2025 20:15:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will present at the Jefferies Global Healthcare Conference on June 4, 2025 at 3:10 p.m. ET. A live webcast will be available on the Alumis website in the "Investors" section under the “Events” page. A rep</description>
</item>
<item>
<title>Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis</title>
<link>https://6ix.com/company/alumis-inc-common-stock/news/alumis-completes-enrollment-pivotal-phase-115500272</link>
<guid isPermaLink="true">https://6ix.com/company/alumis-inc-common-stock/news/alumis-completes-enrollment-pivotal-phase-115500272</guid>
<pubDate>Thu, 29 May 2025 11:55:00 GMT</pubDate>
<description>-Topline readout expected in early Q1 2026-SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the completion of patient enrollment in its pivotal Phase 3 ONWARD clinical program of ESK-001 for the treatment of moderate-to-severe plaque psoriasis. "We are excited to announce the completion of patient enrollment in our pivot</description>
</item>
<item>
<title>Alumis Completes Merger with ACELYRIN</title>
<link>https://6ix.com/company/alumis-inc-common-stock/news/alumis-completes-merger-acelyrin-131000720</link>
<guid isPermaLink="true">https://6ix.com/company/alumis-inc-common-stock/news/alumis-completes-merger-acelyrin-131000720</guid>
<pubDate>Wed, 21 May 2025 13:10:00 GMT</pubDate>
<description>Establishes leading clinical stage biopharma company with differentiated portfolio of therapies and strong balance sheetSOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that it has completed its merger with ACELYRIN, Inc. Each ACELYRIN stockholder will receive 0.4814 shares of Alumis common stock for each share of ACELYR</description>
</item>
<item>
<title>Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements</title>
<link>https://6ix.com/company/alumis-inc-common-stock/news/alumis-reports-first-quarter-2025-200500157</link>
<guid isPermaLink="true">https://6ix.com/company/alumis-inc-common-stock/news/alumis-reports-first-quarter-2025-200500157</guid>
<pubDate>Wed, 14 May 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the quarter ended March 31, 2025, and highlighted recent achievements and upcoming milestones. “We’re seeing strong momentum across our development programs, with our t</description>
</item>
</channel>
</rss>